Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool September 22, 2006 Ryan Fuhrmann	More in Store at Rite Aid? The retail pharmacy posted strong second-quarter sales, and an acquisition could help long-term results. Investors, take note.
The Motley Fool June 21, 2006 Rich Smith	Foolish Forecast: Rite Aid Revival? Will tomorrow's earnings news make it three bad quarters in a row for the retail pharmacy? Investors, take note.
The Motley Fool February 16, 2005 Brian Gorman	Medco's Double-Edged Sword The pharmacy benefit manager's latest financial report indicates that its business remains robust. But is it at the expense of retail pharmacies?
The Motley Fool July 6, 2004 Alyce Lomax	Not Ready for Rite Aid Can the drugstore chain hold a candle to the competition? Its shares are trading at 22 times forward earnings, making it a seemingly less-than-advantageous time to place a bet on them.
The Motley Fool January 5, 2007 Matthew Crews	Rite Aid's Baby Steps If Rite Aid does manage 5% operating margins, this pharmacy chain's shares will get the love they deserve.
The Motley Fool January 3, 2005 Nathan Slaughter	Walgreen Seeing Green Rivals CVS and Rite Aid have a bitter pill to swallow as Walgreen stays strong. While Walgreen's revenues were in line with forecasts, the stronger-than-expected bottom line has the stock gaining ground.
The Motley Fool December 6, 2007 Selena Maranjian	Your Drugs Are in the Mail Order medications online and save. According to a study by the Lewin Group, mail-order pharmacies, such as Medco and Express Scripts, can save you as much as 10% overall.
The Motley Fool December 11, 2006 Matthew Crews	Rite Aid: Comps Mean Competition The pharmacy chain reported positive same-store results for November. Investors, take note.
The Motley Fool September 22, 2005 Stephen D. Simpson	Rite Aid Not Right Yet The bleeding seems to have stopped at this pharmacy, but recovery could be a long and slow road. Intrepid, not to mention patient, investors may see potential here, but there are far better turnaround ideas to be had.
The Motley Fool January 5, 2004 Jeff Hwang	Prescriptions Boost Walgreen Earnings and sales bumped by early flu season and improved non-pharmacy sales.
The Motley Fool July 6, 2007 Lawrence Rothman	Walgreen Does It Again The company continues to impress, posting positive same-store sales results month after month. At a P/E of 21, this stock isn't especially rich, given the solid performance that the company delivers.
The Motley Fool August 31, 2011 Shubh Datta	CVS Caremark Flattened by Higher Costs CVS Caremark profits remained relatively flat this quarter despite a substantial increase in revenue.
The Motley Fool June 11, 2007 Mike Cianciolo	Rite Aid's Generic Sales The drugstore chain gradually increases sales, and catches up to the big boys in one way. Investors, take note.
The Motley Fool June 28, 2005 Mike Cianciolo	Just What Investors Prescribed With another quarter of stellar growth at Walgreen, the stock approaches its highest price ever.
The Motley Fool June 24, 2005 Stephen D. Simpson	Is Rite Aid a Real Value Stock? Reality hasn't caught up with the company's turnaround prospects. Rite Aid must deal with a lot of debt and preferred equity if and when it recovers.
The Motley Fool September 25, 2009 Chris Jones	The First Symptom of Health-Care Troubles? Rite Aid's problems imply bad news for consumers and the health-care system.
The Motley Fool January 4, 2005 Seth Jayson	Rite Aid Still Needs First Aid Sales keep slacking for this tough turnaround. This doesn't mean investors should necessarily jump ship.
The Motley Fool July 27, 2004 Brian Gorman	Medco's Pumped About Generics Generic drugs are actually helping improve Medco's margins, making it a winner with investors and health-care plans.
The Motley Fool June 29, 2007 Ryan Fuhrmann	Rite Aid's Recent Remedy Will increased market clout lead the drugstore operator to new highs? Investors, take note.
The Motley Fool September 26, 2006 Ryan Fuhrmann	Jaw-Dropping Pill-Popping at Walgreen How much longer can investors count on Walgreen's stellar numbers?
The Motley Fool September 27, 2006 Michael P. Cecil	A Drug-Price Avalanche? Wal-Mart shapes the way America buys many products, and its recently announced $4 program for generic prescription drugs may be the harbinger of a major change in prescription-drug sales.
The Motley Fool April 6, 2006 Stephen D. Simpson	Rite Aid Regains Respectability The pharmacy's slow, steady turnaround may not be enough. There have been so many dilutive financing events that it's no longer clear whether common equity shareholders will gain enough bang to compensate for the risk.
The Motley Fool March 9, 2004 Alyce Lomax	February Frenzy at CVS, Rite Aid The flu season's early end hasn't stopped drugstore retailers.
The Motley Fool September 27, 2007 Ryan Fuhrmann	Rite Aid Looks a Little Peaked Bigger doesn't necessarily mean better for the drugstore retailer; it has quite a bit of work to do to convince investors it can successfully manage the empire that it has acquired.
The Motley Fool September 24, 2004 Seth Jayson	Kick This Drug Habit Rite Aid offers slow sales and minuscule shareholder rewards.
The Motley Fool October 4, 2005 Seth Jayson	Same Old Same-Store Story Reports from Walgreen and Rite Aid confirm the obvious. Investors will nearly always do better buying the best company in any given space.
The Motley Fool October 2, 2007 Lawrence A. Rothman	Can the Right Prescription Heal Walgreen? Walgreen is suffering from heightened competition, expenses rising more than 11%, and the company itself predicting its challenges will probably continue into the near future.
The Motley Fool April 13, 2007 Ryan Fuhrmann	Rite Aid's Right-Size Ambitions If the retail pharmacy chain can improve its net margins, reduce debt, and smoothly integrate its latest acquisition, the stock's upside would be substantial.
The Motley Fool September 14, 2006 Ryan Fuhrmann	Playing Defense With the Drugstore Industry Retail pharmacy August sales trends help investors discern the leader in this appealing sector.
The Motley Fool November 4, 2009 Brian Orelli	This One Is Thriving in a Recession Saving customers money makes it easy for Medco.
The Motley Fool August 15, 2005 Bobby Shethia	Walgreen's Prescription for Success The drugstore chain's smart and steady growth makes it a good choice for investors.
The Motley Fool April 11, 2008 Ryan Fuhrmann	Rite Aid Hasn't Fully Recovered Rite Aid needs to be nursed back to health after its acquisition of Brooks Eckerd.
The Motley Fool September 27, 2005 Nathan Slaughter	All Green for Walgreen The retail pharmacy posts record earnings and sales for the 31st consecutive year. Even though Walgreen's latest numbers came up a little short of the mark, it wasn't enough to capture the attention of value investors.
The Motley Fool August 19, 2011 Ilan Moscovitz	Rite Aid Is Cheaper Than You Think Rite Aid tends to generate much more free cash flow than net income, suggesting that -- while things may not exactly be going swimmingly -- the company's stock might be a bit cheaper than many investors realize.
The Motley Fool September 26, 2007 Ryan Fuhrmann	Foolish Forecast: Does Rite Aid Have the Right Rx? The retail pharmacy is set to release it second-quarter financial results. Investors, here is what you can expect to see.
The Motley Fool September 29, 2011 Navjot Kaur	Should You Write Off Rite Aid? Rite Aid posts a relatively better quarter as wellness rewards the company.
The Motley Fool June 25, 2007 Ryan Fuhrmann	Foolish Forecast: Rite Aid Aims for Healthy Growth The drugstore operator is set to report its first-quarter earnings. Investors, here is what you can expect to see.
The Motley Fool January 3, 2006 Stephen D. Simpson	Walgreen Reaps Rewards of Rx The nation's top pharmacy keeps on rolling, but investors might want to keep an eye on the new ventures.
The Motley Fool October 24, 2006 Brian Gorman	Medco's Fringe Benefits Recent developments will present some challenges, but Medco remains a solid long-term investment.
The Motley Fool March 8, 2005 Seth Jayson	Rite Aid Wretched? Value investors may be interested in Rite Aid.
The Motley Fool September 22, 2010 Rich Smith	Foolish Forecast: A Prescription for Rite Aid Investors Here's what you need to know before earnings come out tomorrow.
The Motley Fool January 3, 2012 Shubh Datta	Bright Spots for Rite Aid Better same-store sales help Rite Aid trim losses.
The Motley Fool April 19, 2011 Bryan White	Rising Star Buy: Medco Health Medco has a much brighter future than its current stock price implies.
The Motley Fool January 13, 2009 Dayana Yochim	Fiscal Fitness '09: 6 Ways to Score Cheap(er) Drugs Save more than $200 on prescriptions.
The Motley Fool April 5, 2006 Rich Smith	Foolish Forecast: Rite Aid Writes a Script Although the retail pharmacy isn't setting the world on fire with its turnaround, its gross margins have inched up slightly over the last 18 months. Investors, take note.
The Motley Fool July 6, 2007 Timothy M. Otte	Drugstore Sales Remain Healthy The big four drugstore chains report higher comparable sales in June. Walgreen... CVS... Rite Aid... Long's...
The Motley Fool June 27, 2011 Shubh Datta	All Is Not Yet Right at Rite Aid Drug retailer Rite Aid posts losses in its first fiscal quarter and sees further losses ahead.
The Motley Fool August 16, 2007 Lawrence Rothman	Longs' Prescription for Success Longs Drug Stores may be small, but it excels in its regional niche. Operating primarily on the West Coast, second-quarter results show a company with lots of room for growth.
The Motley Fool April 9, 2007 Mike Cianciolo	CVS: Continued Vigorous Sales The drugstore chain grows sales and itself in March. Investors, take note.
The Motley Fool September 29, 2010 Andrew Bond	Walgreen Surprises the Experts Walgreen posts a great quarter as competition falters.